PLSE on Nasdaq
PULSE BIOSCIENCES, INC.
American surgical and medical instruments and apparatus company2
In its 2026 annual report the company says: “We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells.”5 It is headquartered in Hayward, United States.2 Its shares trade on Nasdaq under the symbol PLSE.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Adagio Medical Holdings, Inc., QTREX Quantum Ltd. or Bluejay Diagnostics, Inc., or pick any stock.
- TickerPLSE on Nasdaq2
- IndustrySurgical & Medical Instruments & Apparatus2
- HeadquartersHayward, United States2
- Incorporated inDE3
- Business address3957 Point Eden Way, Hayward, Ca 945453
- Filer categoryNon-accelerated filer, Smaller reporting company3
- Legal formCorporation2
- LEI529900NJUBI06118FM732
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered addressc/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 69362772
See how the biggest companies compare on our leaderboards
We are a novel ablation company committed to health innovation using our patented Nano-pulse Stimulation (“NPS”) technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to nonthermally clear or kill targeted cells. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation (“nsPFA”) technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. We developed our proprietary nPulse System (formerly known as CellFX), a novel nsPFA delivery platform, and commercialized the initial application of its nsPFA technology to treat benign lesions of the skin. In parallel, we have designed a variety of applicators, or disposables, to explore the potential use of the nPulse platform to treat disorders in othe…5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue1¢$539.0K
- Research and development58¢$44.7M
- Selling, general and admin41¢$32.0M
Out of $350.0K in revenue.6 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Product revenue | $350.0K | $0 |
| Cost of product revenue | $539.0K | $0 |
| Research and development | $44.7M | $32.3M |
| Selling, general and administrative | $32.0M | $23.9M |
| Total cost and expenses | $77.3M | $56.3M |
| Loss from operations | -$76.9M | -$56.3M |
| Interest income | $4.2M | $2.7M |
| Other expense | -$52.0K | -$18.0K |
| Total other income | $4.2M | $2.7M |
| Net loss | -$72.8M | -$53.6M |
| Comprehensive loss | -$72.8M | -$53.6M |
| Net loss per share, basic and diluted (in dollars per share) | -$1.08 | -$0.92 |
| Weighted average common shares outstanding, basic and diluted (in shares) | 67.4M shares | 58.4M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.7M | $118.0M | |
| Accounts receivable | $274.0K | $0 | |
| Inventory | $136.0K | $0 | |
| Prepaid expenses and other current assets | $2.3M | $1.4M | |
| Total current assets | $83.4M | $119.4M | |
| Property and equipment, net | $1.1M | $1.2M | |
| Intangible assets, net | $575.0K | $1.2M | |
| Goodwill | $2.8M | $2.8M | |
| Right-of-use assets | $6.0M | $7.2M | |
| Other assets | $691.0K | $677.0K | |
| Total assets | $94.5M | $132.5M | |
| Accounts payable | $2.8M | $1.7M | |
| Accrued liabilities | $3.6M | $7.0M | |
| Lease liability, current | $1.6M | $1.4M | |
| Total current liabilities | $7.9M | $10.1M | |
| Lease liability, less current portion | $6.0M | $7.5M | |
| Total liabilities | $13.9M | $17.6M | |
| Preferred stock, $0.001 par value; authorized 50,000,000 shares; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; authorized 500,000,000 shares; issued and outstanding 67,839,689 shares and 65,925,503 shares as of December 31, 2025 and 2024, respectively | $68.0K | $66.0K | |
| Additional paid-in capital | $543.9M | $505.3M | |
| Accumulated deficit | -$463.3M | -$390.5M | |
| Total stockholders equity | $80.7M | $114.9M | $44.4M |
| Total liabilities and stockholders equity | $94.5M | $132.5M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 67.8M shares | 65.9M shares | |
| Common stock, shares outstanding (in shares) | 67.8M shares | 65.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $80.7M | $118.0M | |
| Accounts receivable | $274.0K | $0 | |
| Inventory | $136.0K | $0 | |
| Prepaid expenses and other current assets | $2.3M | $1.4M | |
| Total current assets | $83.4M | $119.4M | |
| Property and equipment, net | $1.1M | $1.2M | |
| Intangible assets, net | $575.0K | $1.2M | |
| Goodwill | $2.8M | $2.8M | |
| Right-of-use assets | $6.0M | $7.2M | |
| Other assets | $691.0K | $677.0K | |
| Total assets | $94.5M | $132.5M | |
| Accounts payable | $2.8M | $1.7M | |
| Accrued liabilities | $3.6M | $7.0M | |
| Lease liability, current | $1.6M | $1.4M | |
| Total current liabilities | $7.9M | $10.1M | |
| Lease liability, less current portion | $6.0M | $7.5M | |
| Total liabilities | $13.9M | $17.6M | |
| Preferred stock, $0.001 par value; authorized 50,000,000 shares; no shares issued and outstanding | $0 | $0 | |
| Common stock, $0.001 par value; authorized 500,000,000 shares; issued and outstanding 67,839,689 shares and 65,925,503 shares as of December 31, 2025 and 2024, respectively | $68.0K | $66.0K | |
| Additional paid-in capital | $543.9M | $505.3M | |
| Accumulated deficit | -$463.3M | -$390.5M | |
| Total stockholders equity | $80.7M | $114.9M | $44.4M |
| Total liabilities and stockholders equity | $94.5M | $132.5M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 500.0M shares | 500.0M shares | |
| Common stock, shares issued (in shares) | 67.8M shares | 65.9M shares | |
| Common stock, shares outstanding (in shares) | 67.8M shares | 65.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$72.8M | -$53.6M |
| Depreciation | $406.0K | $512.0K |
| Amortization of intangible assets | $665.0K | $666.0K |
| Stock-based compensation | $21.5M | $13.6M |
| Non-cash lease expense | $1.2M | $923.0K |
| Loss on disposal of fixed assets | $0 | $6.0K |
| Accounts receivable | -$274.0K | $0 |
| Inventory | -$136.0K | $0 |
| Prepaid expenses and other current assets | -$912.0K | -$355.0K |
| Other non-current assets | -$14.0K | -$31.0K |
| Accounts payable | $1.1M | -$201.0K |
| Accrued liabilities | -$3.5M | $3.2M |
| Lease liabilities, net | -$1.4M | -$1.1M |
| Net cash used in operating activities | -$54.1M | -$36.3M |
| Purchases of property and equipment | -$315.0K | -$125.0K |
| Purchases of intangible assets | -$20.0K | $0 |
| Net cash used in investing activities | -$335.0K | -$125.0K |
| Proceeds from issuance of common stock under employee stock purchase plan | $586.0K | $478.0K |
| Proceeds from exercises of warrants, net of issuance costs | $14.1M | $49.4M |
| Proceeds from exercises of stock options | $2.5M | $871.0K |
| Proceeds from issuance of common stock and warrants in relation to rights offering, net of issuance costs | $0 | $59.6M |
| Payment of deferred issuance costs in relation to at-the-market equity offering program | $0 | -$281.0K |
| Net cash provided by financing activities | $17.2M | $110.1M |
| Net (decrease) increase in cash and cash equivalents | -$37.3M | $73.7M |
| Proceeds from exercise of warrants and stock options not yet received | $45.0K | $92.0K |
| Unpaid warrant issuance costs | $2.0K | $13.0K |
| Unpaid amounts related to purchase of equipment | $8.0K | $26.0K |
| Rights offering deemed pro-rata distribution to shareholders | $0 | $47.7M |
| Right-of-use asset obtained in exchange for lease liability | $0 | $830.0K |
No quarter-by-quarter statement was filed.
Corporate structure
PULSE BIOSCIENCES, INC. sits at the top of its group. 4 entities, 2 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of PULSE BIOSCIENCES, INC.
- Robert W. Duggan Filed SCHEDULE 13D/A on PULSE BIOSCIENCES, INC., latest May 13, 2026 (7 filings since Jun 13, 2022)
- PULSE BIOSCIENCES, INC. Hayward, California, United States
- 2783162 Ontario Inc. Subsidiary · Ontario, Canada
- BioElectroMed Corp., a California Corporation Subsidiary · California, United States
- NanoBlate Corp., a Delaware Corporation Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What PULSE BIOSCIENCES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $5.4M6 Dec 31, 2025 | $5.1M6 Dec 31, 2024 | +5.8% |
| Accumulated depreciation | $4.4M6 Dec 31, 2025 | $4.0M6 Dec 31, 2024 | +10.2% |
| Property and equipment, net | $1.1M6 Dec 31, 2025 | $1.2M6 Dec 31, 2024 | −9.4% |
| Operating-lease assets (leased space) | $6.0M6 Dec 31, 2025 | $7.2M6 Dec 31, 2024 | −16.1% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $80.7M6 Dec 31, 2025 | $118.0M6 Dec 31, 2024 | −31.6% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $2.8M6 Dec 31, 2025 | $2.8M6 Dec 31, 2024 | 0% |
| Accumulated amortization | $7.4M6 Dec 31, 2025 | $6.8M6 Dec 31, 2024 | +9.8% |
| Finite-lived intangibles, net | $575.0K6 Dec 31, 2025 | $1.2M6 Dec 31, 2024 | −52.9% |
Inventory
Properties, in its own words
We currently lease approximately 50,300 square feet of premises located in Hayward, California, which is used for our principal operating facility. The term of the lease extends through October 2029.
We also currently lease approximately 2,000 square feet of premises located in Miami, Florida, which is used for our corporate headquarters. The term of the lease is 65 months and it commenced on November 8, 2024.
The rest of Item 2
We believe that our existing and expanded facilities will be sufficient to meet our needs for the foreseeable future.
Item 2 of the 10-K filed Feb 19, 2026.5
Leadership
Who has led PULSE BIOSCIENCES, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
20202025
- Chief executive officerPaul A. Laviolette Jan 13, 2025 to now14
- Chief executive officerBurke Thomas Barrett May 22, 2024 to Jul 22, 202415
- Chief executive officerKevin Patrick Danahy Sep 27, 2022 to Nov 17, 202316
- Chief executive officerDarrin Uecker May 13, 2016 to Mar 24, 202117
- PresidentBurke Thomas Barrett May 22, 2024 to Jul 22, 202415
- PresidentDarrin Uecker May 13, 2016 to Mar 24, 202117
- Chief financial officerSandra Gardiner Nov 19, 2019 to Feb 28, 202218
- Chief financial officerBrian B. Dow May 13, 2016 to May 18, 201719
- Chief operating officerLiane Rae Teplitsky Aug 28, 2026 to now20
Board members and other officers (15)
- Chief Technology OfficerDarrin Uecker May 2, 2023 to now21
- Chief Commercial OfficeKevin Patrick Danahy Mar 22, 2022 to now22
- Chief Strategy OfficerMitchell E. Levinson Aug 20, 2021 to Sep 30, 202423
- EVP & GM, DermatologyEd Ebbers Jan 18, 2019 to Jun 3, 202124
- Board memberBurke Thomas Barrett May 22, 2024 to Jul 22, 202415
- Board memberPaul A. Laviolette Aug 13, 2024 to now25
- Board memberLaureen Debuono Oct 6, 2021 to Oct 6, 202126
- Board memberShelley D. Spray Nov 29, 2021 to Jun 6, 202327
- Board memberMaky Zanganeh Feb 13, 2017 to now28
- Board memberManmeet Singh Soni Nov 6, 2017 to now29
- Board memberRobert W. Duggan Nov 6, 2017 to now30
- Board memberThomas J. M. D. Fogarty Nov 6, 2017 to May 17, 201931
- Board memberDarrin Uecker May 13, 2016 to now17
- Board memberMitchell E. Levinson May 13, 2016 to May 9, 202332
- Board memberThierry B. Thaure May 13, 2016 to May 18, 201733
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- 2783162 Ontario Inc. Ontario4
- BioElectroMed Corp., a California Corporation California4
- NanoBlate Corp., a Delaware Corporation Delaware4
- Pulse Biosciences BV Netherlands4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- Electroblate, Inc.Nov 13, 2014 to Nov 13, 20143
Timeline
- Oct 14, 20268-K Other events34
- Oct 7, 20268-K Other events35
- Sep 15, 20268-K Other events36
- Sep 15, 20268-K Entered a material agreement; Ended a material agreement37
- Aug 6, 20268-K Results of operations38
- Aug 6, 20268-K Entered a material agreement39
- Jul 29, 20268-K Other events40
- Jun 12, 20268-K Shareholder vote41
- Jun 10, 20268-K Other events42
- May 6, 20268-K Other events43
- May 4, 20268-K Results of operations; Other events44
- Apr 27, 20268-K Regulation FD disclosure45
- Jan 13, 2025New chief executive Paul A. Laviolette becomes CEO14
- May 22, 2024New chief executive Burke Thomas Barrett becomes CEO15
- Sep 27, 2022New chief executive Kevin Patrick Danahy becomes CEO16
- May 13, 2016New chief executive Darrin Uecker becomes CEO17
Calendar
Coming up
- Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.29) a share, on Nov 5, 2025.46
When it reported results
- Aug 6, 2026Reported quarterly or annual results38
- May 4, 2026Reported quarterly or annual results44
- Feb 19, 2026Reported quarterly or annual results47
- Nov 5, 2025Reported quarterly or annual results48
- Aug 12, 2025Reported quarterly or annual results49
- May 8, 2025Reported quarterly or annual results50
- Mar 28, 2025Reported quarterly or annual results51
- Oct 30, 2024Reported quarterly or annual results52
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
325 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 106 major events, 120 insider forms, 7 large holders, 70 other. The latest 20:
- Oct 14, 20268-K EDGAR
- Oct 7, 20268-K EDGAR
- Sep 15, 20268-K EDGAR
- Sep 15, 2026424B5 EDGAR
- Sep 15, 20268-K EDGAR
- Sep 2, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20263 EDGAR
- Aug 28, 20264 EDGAR
- Aug 28, 20263 EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 2026424B5 EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 29, 20268-K EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
- Jun 15, 20264 EDGAR
The 325 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
50 open-market trades by officers, directors and large owners since October 2021: 32 buys and 18 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,001 | $49.95 | $50.0K | Form 4 |
| Aug 31, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,024 | $48.80 | $50.0K | Form 4 |
| Aug 28, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,034 | $48.35 | $50.0K | Form 4 |
| Aug 26, 2026 | Teplitsky Liane RaeChief Operating Officer | Buy | 1,036 | $48.24 | $50.0K | Form 4 |
| May 11, 2026 | DUGGAN ROBERT WDirector | Buy | 660,233 | $19.69 | $13.0M | Form 4 |
| May 11, 2026 | LAVIOLETTE PAUL AChief Executive Officer | Buy | 15,000 | $19.69 | $295.4K | Form 4 |
| May 11, 2026 | LAVIOLETTE PAUL AChief Executive Officer | Buy | 15,000 | $19.69 | $295.4K | Form 4 |
| May 11, 2026 | DUGGAN ROBERT WDirector | Buy | 660,233 | $19.69 | $13.0M | Form 4 |
| Feb 18, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 5,000 | $23.64 | $118.2K | Form 4 |
| Feb 17, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.63 | $472.6K | Form 4 |
| Feb 13, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.53 | $470.6K | Form 4 |
| Feb 12, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.37 | $467.4K | Form 4 |
| Feb 11, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $25.20 | $504.0K | Form 4 |
| Feb 10, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $23.52 | $470.4K | Form 4 |
| Feb 9, 2026 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $21.45 | $429.0K | Form 4 |
| Oct 2, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 4,600 | $18.53 | $85.2K | Form 4 |
| Sep 19, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 400 | $18.48 | $7.4K | Form 4 |
| Sep 18, 2025 | Danahy Kevin PatrickChief Commercial Officer | Sale | 20,000 | $18.49 | $369.8K | Form 4 |
| Sep 17, 2025 | UECKER DARRINChief Technology Officer | Sale | 20,000 | $16.21 | $324.2K | Form 4 |
| Sep 16, 2025 | UECKER DARRINChief Technology Officer | Sale | 25,000 | $16.28 | $407.0K | Form 4 |
All 50 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Robert W. DugganSCHEDULE 13D/A, 7 filings Jun 13, 2022 to May 13, 202653
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Paul A. LaViolette | 68 | $708.5K | $7.4M54 |
| 2025 | Jon Skinner | $366.7K | $2.8M54 | |
| 2025 | Darrin R. Uecker | 60 | $540.3K | $869.9K54 |
| 2025 | Kevin P. Danahy | $525.0K | $854.6K54 | |
| 2024 | Former ChiefExecutive Officer and Former Director | $327.3K | $9.1M54 | |
| 2024 | Former Chief Commercial Officer | $512.5K | $1.9M54 | |
| 2024 | Chief Technology Officer and Director | $512.5K | $616.4K54 | |
| 2023 | Former Chief Commercial Officer | $433.3K | $6.2M54 | |
| 2023 | Chief Technology Officer and Director | $433.3K | $5.4M54 | |
| 2023 | Former Chief Strategy Officer and Former Director | $369.6K | $1.6M54 | |
| 2022 | Former Chief Commercial Officer | $350.0K | $1.6M54 | |
| 2022 | Chief Technology Officer and Director | $485.9K | $487.2K54 | |
| 2022 | Former Chief Strategy Officer and Former Director | $360.0K | $361.3K54 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How PULSE BIOSCIENCES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPULSE BIOSCIENCES, INC.1
- CIK0001625101
- Employer ID (EIN)46-56965975
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address3957 Point Eden Way, Hayward, CA 945451
- Phone510-906-46001
- Shares outstanding71,322,607 as of Jul 31, 202612
- Public float$266.2M as of Jun 30, 20255
- AuditorDeloitte & Touche LLP, San Francisco, California PCAOB ID 34; no auditor attestation of internal control over financial reporting5
- On EDGAR sinceNov 13, 20141
- Filings639 in all: 4 (196), 8-K (171), 10-Q (32), 3 (27), CORRESP (27), UPLOAD (22), SC 13D/A (17), EFFECT (13)1
All 43 form types
S-8 (13), DEF 14A (12), S-3 (11), 10-K (10), S-3/A (10), SD (7), 144 (6), 424B5 (6), 4/A (5), D (4), DEFA14A (4), SC 13G (4), 10-K/A (3), 424B3 (3), 424B4 (3), FWP (3), PRE 14A (3), S-1/A (3), SC 13G/A (3), 10-Q/A (2), 3/A (2), 8-K/A (2), SC 13D (2), SCHEDULE 13D/A (2), 424B2 (1), 5 (1), 8-A12B (1), 8-K12B (1), CERTNAS (1), CT ORDER (1), NT 10-Q (1), POS AM (1), S-1 (1), S-3MEF (1), S-8 POS (1)
- Latest filingsAnnual report (10-K) Feb 19, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) May 11, 2026
Latest 8-K (8-K) Oct 14, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.001 per share | PLSE | Nasdaq |
From the cover page of the 10-K filed Feb 19, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks PULSE BIOSCIENCES, INC. names in Item 1A of its 10-K filed Feb 19, 2026: 61 risks under these headings, as written.5
- Risks Relating to Our Business, Industry and Financial Condition
- Because we have had a limited operating history and no significant revenue stream, it is difficult to evaluate the future of our business.
- We have not generated significant revenue, and we may never become profitable.
- We can give no assurance that our internal and external sources of liquidity will be sufficient for our cash requirements.
- If we are unable to obtain sufficient funding, we may be unable to execute our business plan and fund operations. We may not be able to obtain additional financing on commercially reasonable terms, or at all.
- Because our business is not profitable, from time to time, we may undergo a reduction in force to reduce our operating expenses. However, any corporate restructuring or headcount reduction may not result in anticipated savings, could result in total costs and expenses and attrition that are greater than expected and could disrupt our business.
- Our revenue and future profitability are entirely dependent upon one family of products, the nPulse System, and one platform technology, Nano-pulse Stimulation.
- We may fail to meet our publicly announced guidance or other expectations about our business and future operating results, which could cause our stock price to decline.
- Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations; our product revenues are limited and our profit margins are uncertain.
- Because we operate in highly competitive markets, we can expect to face competition from large well-established manufacturers of medical technologies, devices and similar products; we may not be able to compete effectively against companies with significantly more resources.
- We may rely on third parties for our sales, marketing, manufacturing, and/or distribution activities, and these third parties may not perform satisfactorily.
- If we lose key management personnel, our ability to identify, develop and commercialize new or next generation product candidates will be impaired, could result in loss of markets or market share and could make us less competitive.
The other 50 risks
- There is a limited talent pool of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy.
- We have had limited experience selling the nPulse System.
- Rapidly changing technology in life sciences could make the products we are developing obsolete.
- If we are unable to manage the anticipated growth of our business, our future revenue and operating results may be harmed.
- We must successfully educate and train surgeons and their staff on the proper use of the nPulse System; if our customers do not adopt our technology into their medical practices, or adopt our technology slower than expected, our business could suffer.
- We may encounter manufacturing problems or delays that could result in lost revenue or slower than anticipated product development. Additionally, we currently rely on third-party suppliers for critical components needed to manufacture the nPulse System and related applicators. Any problems experienced by these suppliers could result in a delay or interruption of their supply to us and, as a result, we may face delays in the development and commercialization of products.
- We may not become commercially viable if our ultimate commercialized products or related treatments fail to obtain an adequate level of reimbursement by Medicare and other third-party payers.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
- We have a substantial amount of goodwill and intangible assets which over time may have to be written down as we make the required periodic assessments as to their value as reflected in our financial statements.
- Risks Related to Product Development and Product-Related Risks
- Our nPulse System and any future product candidates may cause serious adverse side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial desirability or result in significant negative consequences.
- Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
- Our long-term growth depends on our ability to develop marketable products to treat AF, tumors and nodules through our research and development efforts, and if we fail to do so we may be unable to compete effectively or we may decide to scale back or eliminate some or all of our activities or otherwise curtail, suspend or discontinue our operations entirely.
- Interim “top-line” and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.
- If we fail to maintain necessary regulatory clearance for our products, or if clearances or approvals for future devices and indications are delayed or not issued, the commercial prospects for our nPulse System and other NPS technologies would be harmed.
- The mechanism of action of our NPS technology platform has not been fully determined or validated.
- We may find it difficult to enroll patients in our clinical trials. If we cannot enroll a sufficient number of eligible patients to participate in our clinical trials, we may not be able to initiate or continue them, which could delay or prevent development of our product candidates.
- Laboratory conditions differ from commercial conditions and field conditions, and the safety and effectiveness of our product candidates may depend on the technique of the user.
- Issues with our firmware and software may negatively affect the function of our devices.
- Risks Related to Intellectual Property, Cybersecurity, Data Privacy, & Litigation
- If we are unable to protect our intellectual property, then our financial condition, results of operations and the value of our technology and products could be adversely affected.
- Litigation or third-party claims of intellectual property infringement or challenges to the validity of our patents would require us to use resources to protect our technology and may prevent or delay our development, regulatory approval or commercialization of our product candidates.
- Our intellectual property rights will not necessarily provide us with competitive advantages.
- If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected.
- If we are unable to protect the intellectual property used in our products, others may be able to copy our innovations which may impair our ability to compete effectively in our markets.
- We may not be able to protect our intellectual property rights throughout the world.
- If our information technology systems or data, or those of third parties upon whom we rely, are or were compromised, we could experience adverse consequences resulting from such compromise, including, but not limited to, regulatory investigations and actions; litigation (including class claims); fines and penalties; a disruption of our business operations such as our clinical trials; reputational harm; loss of revenue and profits; and other adverse consequences.
- Implementation of artificial intelligence and machine learning technologies may result in legal and regulatory risks, reputational harm, or other adverse consequences to our business.
- Product liability lawsuits against us could cause us to incur substantial liabilities and limit commercialization of our products or any future products that we may develop.
- Risks Related to Government Regulation
- We are subject to stringent domestic and foreign regulation. Any unfavorable regulatory action or adverse change in law may materially and adversely affect our future financial condition and business operations and prospects.
- Disruptions in the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel or otherwise prevent new product candidates and services from being developed or commercialized in a timely manner, which could negatively impact our business.
- All our product development depends upon maintaining strong working relationships with physicians.
- We are subject to healthcare and other laws and regulations relating to our business and could face substantial penalties if we are determined not to have fully complied with such laws, which could have an adverse impact on our business.
- To obtain the necessary device approvals or clearances from regulatory authorities for our future product candidates, we will have to conduct various preclinical and clinical tests, which may be costly and time consuming, and may not provide results that will allow us to seek regulatory approval or clearance.
- Even if a potential device or product ultimately is cleared or approved by regulatory authorities, it may be cleared or approved only for narrow indications which may render it commercially less viable.
- We will be subject to ongoing requirements and inspections that could lead to the restriction, suspension or revocation of our clearance.
- Our employees, collaborators and other personnel may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.
- We are subject to environmental regulations and any failure to comply with applicable laws could subject us to significant liabilities and harm our business.
- Risks Related to Owning Our Common Stock
- The price of our common stock has been, and we expect it to continue to be, highly volatile, and you may be unable to sell your shares at or above the price you paid to acquire them.
- Sales or purchases of shares of our common stock may adversely affect the market for our common stock.
- We do not know whether an active, liquid and orderly trading market will exist for our common stock and as a result it may be difficult for you to sell your common stock.
- Concentration of ownership by our principal stockholder limits the ability of others to influence the outcome of director elections and other transactions requiring stockholder approval, or create the potential for conflicts of interest.
- Robert W. Duggan’s controlling ownership position may impact our stock price and may deter or prevent efforts by others to acquire us, which could prevent our stockholders from realizing a control premium.
- We have incurred and will continue to incur costs as a result of operating as a public company and our management has been and will be required to devote substantial time to public company compliance initiatives.
- We are a “smaller reporting company”; we cannot be certain if the applicable reduced disclosure requirements will make our common stock less attractive to investors.
- We have not paid dividends in the past and have no plans to pay dividends.
- Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock.
- General Risk Factors
- Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
- If we experience material weaknesses in the future or otherwise fail to maintain an effective system of internal control over financial reporting in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.
- If the interpretations, estimates or judgments we use to prepare our financial statements prove to be incorrect, investors and others may lose confidence in our financial data, which could cause our stock price to decline.
- We may become involved in litigation that may materially adversely affect us.
- Our facilities in California are located near known earthquake faults, and the occurrence of an earthquake or other catastrophic disaster could cause damage to our facilities and equipment, which could require us to cease or curtail operations.
Legal proceedings
From time to time, we may be involved in various legal proceedings arising in the ordinary course of business. We are not presently a party to any legal proceedings that, in the opinion of management, could have a material adverse effect on our results of operations or financial condition. Regardless of outcome, however, any litigation could have an adverse impact on us because of defense and settlement costs, diversion of management resources, negative publicity, reputational harm, and other factors.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24SEC EDGAREd Ebbers, EVP & GM, Dermatology
- 25SEC EDGARPaul A. Laviolette, Board member
- 26SEC EDGARLaureen Debuono, Board member
- 27SEC EDGARShelley D. Spray, Board member
- 28SEC EDGARMaky Zanganeh, Board member
- 29SEC EDGARManmeet Singh Soni, Board member
- 30SEC EDGARRobert W. Duggan, Board member
- 31
- 32SEC EDGARMitchell E. Levinson, Board member
- 33SEC EDGARThierry B. Thaure, Board member
- 34SEC EDGAROther events
- 35SEC EDGAROther events
- 36SEC EDGAROther events
- 37
- 38SEC EDGARResults of operations
- 39SEC EDGAREntered a material agreement
- 40SEC EDGAROther events
- 41SEC EDGARShareholder vote
- 42SEC EDGAROther events
- 43SEC EDGAROther events
- 44SEC EDGARResults of operations; Other events
- 45SEC EDGARRegulation FD disclosure
- 46NasdaqNasdaq calendar
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54